Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Genomic-based solutions can help identify which cancer patients will respond better to treatment based on biomarkers, said David Fabrizio of Foundation Medicine, Inc.
Transcript (slightly modified)
Do you think the immunotherapy field needs a different approach to predict patient response to treatment?
Yeah, absolutely. I think right now IHC [immunohistochemistry] is the current method, and I spoke to some of the limitations, I think there are significant limitations to IHC. I think we need genomic-based solutions, quantitative solutions that can be universally adopted. So something like tumor mutational burden [TMB], which can be measured through comprehensive genomic profiling, is a solution.
And we know this because we’ve looked at the utility over more than 500 patients right now, in disease areas that include non-small cell lung cancer, bladder cancer, and metastatic melanoma, and we’ve published these results showing that you can identify biomarker-positive patients that in some cases lived 3 times longer than the negative group without their disease getting any worse, and that’s in lung cancer. In the bladder and melanoma studies, the biomarker-positive groups for TMB weren’t reached, the median survival wasn’t reached, compared to the ones who were negative. So it does have resounding clinical utility, and I think we’re going to start to see that expand to other indications.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More